Q-omics provides the consensus-scored NECAP1P2 profile across patient tissues and cancer cell-line models. NECAP1P2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, NECAP1P2 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, NECAP1P2 RNA expression shows 12,064 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight LUSC, KIRC, and LAML as cancer lineages where NECAP1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NECAP1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NECAP1P2 survival associations across molecular data types. NECAP1P2 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NECAP1P2 RNA expression–survival associations across cancer types. High NECAP1P2 expression shows unfavorable associations in LUSC, THYM, READ, KIRP and OV, but favorable associations in LUAD. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .014). Together, the overview and detailed table identify LUSC as the clearest survival context for NECAP1P2 RNA expression.
This table summarizes NECAP1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NECAP1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NECAP1P2 shows lower tumor expression in LUAD and higher tumor expression in KIRC, KICH and CHOL. The KIRC box plot shows higher NECAP1P2 RNA expression in tumor versus normal tissue (log2 FC = +0.030, t-test p = .006).
This table shows molecular features associated with NECAP1P2 in patient tissues and cancer cell lines. In patient samples, NECAP1P2 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
